The user shared 6-month results using finasteride, minoxidil, ketoconazole shampoo, vitamin D, calcium, and biotin, showing significant improvement. Another user praised the results as excellent.
Taking finasteride alone did not stop hair loss, but adding vitamin D3 and iron supplements improved hair coverage and quality. It's important to check and address deficiencies, but caution is advised with iron supplementation without medical guidance.
The conversation discusses the effectiveness of an eyebrow serum containing Myristoyl Pentapeptide and Biotinoyl Tripeptide for hair growth. The user seeks information on other topical products with similar peptides for hair growth.
A 28-year-old male has been taking 1mg finasteride daily since January 26, 2024, with noticeable hair regrowth and no side effects. He also takes Vitamin D3 and a multivitamin daily and advises others to try finasteride despite potential side effects.
The user has been treating hair loss with finasteride, dutasteride, oral minoxidil, and pyrilutamide for several years without success and is experiencing an inflamed scalp, possibly due to seborrheic dermatitis. They are seeking advice on additional treatments after these methods failed to improve their condition.
The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
A user shared progress pictures showing significant hair regrowth after 3 months using a topical foam with 5% Minoxidil and 0.25% Finasteride. They plan to add derma rolling to their routine.
A 29-year-old is using oral minoxidil, finasteride, hormone replacement therapy (HRT), and microneedling for hair regrowth. They started balding at 20, worsened at 25, and are transitioning with testosterone blockers.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
The conversation is about a user's 3-month hair loss treatment using topical minoxidil, oral finasteride, a derma roller, ketoconazole shampoo, rosemary oil, and vitamin D supplements, alongside weight loss. Users discuss shedding, vitamin D benefits, and reducing sugar intake.
The user experienced positive hair regrowth using topical minoxidil, along with other factors like shorter hair, castor oil, and hair masks. The user is optimistic about further progress and wants to avoid baldness.
The user experienced noticeable hair regrowth after three months of using topical minoxidil and microneedling, along with lifestyle changes. They plan to start using topical finasteride soon to maintain results.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.
A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
A user shared their 3-month progress using a topical solution containing 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, reporting improvements in thinning areas. Another user mentioned using oral finasteride, oral minoxidil, dutasteride, and minoxidil foam, discussing costs and side effects.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
A 22-year-old male has been using oral finasteride (1.2mg) and oral minoxidil (2.5mg) daily for 3.5 months, along with vitamin D, fish oil, iron, and biotin, and reports significant hair growth without side effects. The user plans to continue the treatment and is considering cutting hair to assess progress more accurately.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.